Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus Nab-Paclitaxel for Metastatic Breast Cancer-In Reply

JAMA Oncol. 2019 Jun 1;5(6):908-909. doi: 10.1001/jamaoncol.2019.0317.

Authors

Sylvia Adams¹, Luciana Molinero²

Affiliations

¹ New York University Perlmutter Cancer Center, New York, New York.
² Oncology Biomarkers Development, Genentech Inc, South San Francisco, California.

PMID: 30998805
DOI: 10.1001/jamaoncol.2019.0317

No abstract available

Publication types

Comment

MeSH terms

Albumins*
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Humans
Paclitaxel*

Substances

130-nm albumin-bound paclitaxel
Albumins
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
atezolizumab
Paclitaxel